Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by walkingredon Apr 18, 2016 8:06pm
575 Views
Post# 24781482

Question to Fred about RS with reply.

Question to Fred about RS with reply.SENT BY ME

Good morning Fred,

I’m looking to get information on the proposed stock consolidation.

I understand there is guidance from really smart people but I’m trying to understand if this is a topic that must be visited annually, or something company suggesting is best for overall performance and therefore it will be a discussion at AGM?


REPLY FROM FRED


Good afternoon WalkingRed,

It will definitely be discussed at the AGM and just like last year, we will make sure to explain again that we are asking for such a vote just in case we decide to proceed with a NASDAQ listing and need it to meet the "famous" sweet spot" price range of $12 to $15 that is recognized as the best possible price for a listing in the US in order to draw attention of the right se of institutional investors.

Plan A is still and always was to deliver first and foremost on the expected clinical and operational milestones and get there organically. It is just a precautionary measure in case we would need to move faster. 

Hope this helps,

Best regards,

Fred
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse